Similarly, epidermal growth factor receptor (EGFR)-targeted antibody (cetuximab) anchoring PL–DOX (EGFR–PL–DOX) targets EGFR-positive breast cancer cells. This evidence concerns the gene EGFR and breast carcinoma.